Flag of the European Union EU Clinical Trials Register Help

Clinical trials for parkinson

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    443 result(s) found for: parkinson. Displaying page 1 of 23.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000801-30 Sponsor Protocol Number: E2007-G000-318 Start Date*: 2007-08-01
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) PL (Completed) FR (Completed) ES (Completed) IT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002339-26 Sponsor Protocol Number: E2007-G000-303 Start Date*: 2006-10-05
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor ...
    Medical condition: Levodopa treated Parkinson's disease patients with motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) CZ (Completed) HU (Completed) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) DE (Completed) ES (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017182-38 Sponsor Protocol Number: IPX066-B09-03 Start Date*: 2010-05-14
    Sponsor Name:Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
    Full Title: An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease
    Medical condition: Idiopathic Parkinson´s disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011541-24 Sponsor Protocol Number: TVP-1012/501 Start Date*: 2009-10-09
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000148-40 Sponsor Protocol Number: PDSTAT2015 Start Date*: 2015-11-09
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    18.0 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-005234-39 Sponsor Protocol Number: 2939111 Start Date*: 2005-05-27
    Sponsor Name:Orion Corporation, ORION PHARMA, Finland
    Full Title: Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) FI (Completed) IE (Completed) DE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-002697-37 Sponsor Protocol Number: 14/0382 Start Date*: 2015-04-15
    Sponsor Name:University College London
    Full Title: Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease
    Medical condition: Parkinson's Disease Nocturia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    17.1 10029205 - Nervous system disorders 10034007 Parkinson's disease NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000833-12 Sponsor Protocol Number: NW-1015/015/III/2003 Start Date*: 2004-12-02
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients ...
    Medical condition: Early idiopathic Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10013113 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000835-27 Sponsor Protocol Number: NW-1015/017/III/2003 Start Date*: 2004-12-03
    Sponsor Name:NEWRON PHARMACEUTICALS
    Full Title: A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with ear...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061536 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008210-38 Sponsor Protocol Number: 2008_02/0841 Start Date*: 2009-04-16
    Sponsor Name:Chru de Lille
    Full Title: Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I”
    Medical condition: Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    9.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000405-23 Sponsor Protocol Number: Versio_1 Start Date*: 2018-03-27
    Sponsor Name:Juha Rinne / PET Centre
    Full Title: In vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD)
    Medical condition: Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004006-18 Sponsor Protocol Number: ParkinsonDPI-3 Start Date*: 2018-06-07
    Sponsor Name:Pharmaceutical Technology and Biopharmacy, University of Groningen
    Full Title: Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease
    Medical condition: Parkinson's disease is a progressive neurodegenerative disorder characterized by a lack of dopamine production due to the loss of dopamine producing cells in the substantia nigra. This lack of dopa...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005422-35 Sponsor Protocol Number: Start Date*: 2015-05-28
    Sponsor Name:Imperial College London-Imperial College Healthcare NHS Trust
    Full Title: THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO.
    Medical condition: Levodopa induced dyskinesias within Parkinson's disease.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000102-11 Sponsor Protocol Number: NL55949 Start Date*: 2016-11-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.
    Medical condition: Parkinson's disease patients with refractory visual hallucinations
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000867-65 Sponsor Protocol Number: C_30990_P1_06 Start Date*: 2021-04-19
    Sponsor Name:Luye Pharma Switzerland AG
    Full Title: Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease
    Medical condition: Idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023756-82 Sponsor Protocol Number: TUD-RaSPar-051 Start Date*: 2011-07-13
    Sponsor Name:Dresden University of Technology
    Full Title: Rasagiline treatment for Sleep disorders in Parkinson´s disease
    Medical condition: sleep disturbances/sleep disorders in patients with Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002239-41 Sponsor Protocol Number: SC17.01 Start Date*: 2018-02-16
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Effects of Safinamide therapy on reuroplasticity in patients with Parkinson's disease
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004112-21 Sponsor Protocol Number: VorDE-PD Start Date*: Information not available in EudraCT
    Sponsor Name:IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
    Full Title: TOLERABILITY, SAFETY AND EFFICACY OF VORTIOXETINE FOR TREATMENT OF DEPRESSION IN PARKINSON’S DISEASE: A 16 WEEK OPEN LABEL STUDY
    Medical condition: Depression in Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000361-35 Sponsor Protocol Number: E2007-E044-205 Start Date*: 2004-10-18
    Sponsor Name:Eisai Limited
    Full Title: A 48-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON’S DISEASE WITH “WEARING OFF” MOTOR FLUCTUATIONS ...
    Medical condition: Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:37:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA